Sopharma AD-Sofia (XBUL:SFA) Short-Term Debt: €157 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:SFA Sopharma AD-Sofia XBUL:SFA
56 GF Score
Price €2.40
GF Value €2.13
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Short-Term Debt?

Sopharma AD-Sofia XBUL:SFA +2.13% 56 Short-Term Debt is €157 Mil as of Jun. 2026. GuruFocus rates XBUL:SFA with a GF Score™ of 56/100 and a GF Value™ of €2.13 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Sopharma AD-Sofia's Short-Term Debt for the quarter that ended in Jun. 2026 was €157 Mil.

Sopharma AD-Sofia's quarterly Short-Term Debt declined from Dec. 2025 (€193 Mil) to Mar. 2026 (€177 Mil) and declined from Mar. 2026 (€177 Mil) to Jun. 2026 (€157 Mil).

Sopharma AD-Sofia's annual Short-Term Debt increased from Dec. 2023 (€105 Mil) to Dec. 2024 (€156 Mil) and increased from Dec. 2024 (€156 Mil) to Dec. 2025 (€193 Mil).

Sopharma AD-Sofia Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sopharma AD-Sofia Short-Term Debt Related Terms

Sopharma AD-Sofia Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Short-Term Debt Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 118.83 86.13 105.12 156.18 193.22

Sopharma AD-Sofia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.82 199.02 193.22 176.76 157.41
XBUL:SFA
56GF Score
Sopharma AD-Sofia XBUL:SFA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €157 Mil mean?
Sopharma AD-Sofia (XBUL:SFA) has a Short-Term Debt of €157 Mil as of Jun. 2026.
Is Sopharma AD-Sofia's Short-Term Debt too high?
Sopharma AD-Sofia's current Short-Term Debt is €157 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Short-Term Debt compare to MCK and COR?
Sopharma AD-Sofia's Short-Term Debt of €157 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Distribution company?
A good Short-Term Debt depends on the Medical Distribution industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sopharma AD-Sofia's current Short-Term Debt is €157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (XBUL:SFA) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.13, compared to a current price of €2.40 — trading 12.7% above its estimated fair value. The current Short-Term Debt is €157 Mil. Sopharma AD-Sofia's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sopharma AD-Sofia (XBUL:SFA), the current Short-Term Debt is €157 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (XBUL:SFA) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued. The current stock price of €2.40 is trading 12.7% above its estimated GF Value™ of €2.13. GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.

Key valuation signals for XBUL:SFA:

  • Short-Term Debt: €157 Mil
  • GF Value™: €2.13 vs. price of €2.40 (12.7% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the XBUL:SFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:Poland3JR:Germany
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
56GF Score

Get the complete analysis for XBUL:SFA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price
€2.13
GF Value